OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa
1. Date of occurrence of the event: Feb 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …
Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court
Parties to the legal matter: Michael Chang (Chairman); Youe-Kong Shue (Former Vice Chairman); Amy Hung (Former General Manager); Tony Yu (Former Chief Science Officer); Jon-Jin Liao (Former Medical Business Director) …
OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference
1. Date of the event: Jan 12, 2021 2. Time: 00:00:00 NST 3. Location: Virtual Event 4. Summary: OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference …
OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference
Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development …
OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (Announcement of base day and trading counterparty)
1. Type of merger and acquisition (e.g., merger, spin-off, acquisition, or share transfer): Share transfer 2. Date of occurrence of the event: Dec 31, 2020 3. Names of companies participating …
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by National Medical Products Administration (NMPA) to proceed Phase III human clinical study
1. Date of occurrence of the event: Dec 25, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities
Contents: 1.Date of institutional investor conference: Dec 21, 2020 2.Time of institutional investor conference: 14:30:00 NST 3.Location of institutional investor conference: Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., …
OBI licensed the Intellectual Property Right of Global Aesthetic Medicine to a designated company
Contents: 1.Date of occurrence of the event: Dec 04, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: …
OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (supplement base date)
1.Type of merger and acquisition (e.g. merger, spin-off, acquisition, or share transfer): Share transfer 2.Date of occurrence of the event: Nov 27, 2020 3.Names of companies participating in the merger …
OBI received the reply from FDA about the Investigational Device Exemption (IDE) of Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424
1. Date of occurrence of the event: Nov 23, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4. …